| 0.37 0 (0%) | 11-18 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Seelos Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the discovery, development, and eventual commercialization of innovative therapies. These treatments primarily target central nervous system (CNS), respiratory, and various other medical conditions. The company's pipeline includes several key clinical-stage candidates. Foremost among these is SLS-002, an intranasally administered racemic ketamine, being investigated for rapidly alleviating acute suicidal ideation and behavior in individuals with major depressive disorder (MDD). Another significant program, SLS-005, acts as a protein stabilizer, addressing amyotrophic lateral sclerosis (ALS) and Sanfilippo syndrome. Additionally, SLS-006 is a partial dopamine agonist under development for the treatment of Parkinson's disease (PD). Beyond its clinical efforts, Seelos maintains a robust preclinical portfolio exploring novel mechanisms. This includes SLS-007, an anti-alpha-synuclein peptidic inhibitor designed to combat Parkinson's disease, and SLS-008, an orally bioavailable antagonist targeting chemoattractant receptor-homologous molecule, intended for chronic inflammatory conditions such as asthma and specific pediatric orphan diseases. Other early-stage candidates comprise SLS-004 for Parkinson's disease; SLS-010, an oral histamine H3A receptor antagonist aimed at narcolepsy and related sleep disorders; and SLS-012, an injectable formulation for managing post-operative pain. Founded in 1987, Seelos Therapeutics, Inc. operates from its headquarters situated in New York, New York.
Thu, 24 Apr 2025
SEELOS THERAPEUTICS (SEEL) Stock Price, News & Analysis - Stock Titan
Tue, 15 Oct 2024
Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market - PR Newswire
Fri, 24 Nov 2023
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|